Affibody® molecules are suitable for a broad range of applications, including targeted therapy, diagnostic imaging, protein purification, research reagents for protein capture and detection, and enzyme inhibition.

Affibody® molecules with specificity and selectivity for tumor markers can be used for non-invasive early detection by diagnostic imaging of tumors, and to monitor disease by detecting tumor progression or regression in response to cancer therapy.

Their short plasma circulation time is optimal for molecular imaging and may be extended up to weeks using Affibody’s Albumod™ technology, resulting in a molecule that is optimized for targeted therapy.

Affibody has created a large library consisting of more than ten billion Affibody® molecules based on a second generation scaffold, from which binders to given targets are selected.

Key features include:

• Small size (1/25th the size of a monoclonal antibody)
• High selectivity and affinity (high potency)
• Rapid and reversible folding (extreme stability)
• Flexible low cost production (synthesis or recombinant)
• Flexible engineering and formatting (modified properties)

The library of Affibody® molecules, all with unique binding sites, has been created by randomization of 13 amino acid residues yielding a whole new surface on one side of the protein. The common backbone of the Affibody® molecules is an engineered compact three-helix bundle protein domain.

The company has developed a second generation Affibody® molecule scaffold, having improved properties including increased stability and improved amenability for peptide synthesis in large scale. A patent application regarding this second generation Affibody® platform was filed 2007.